Studi Efek Samping Obat Antituberkulosis (OAT) Pada Pasien TB Paru

Nur Rasdianah, Madania Madania, Teti Sutriati Tuloli, Widy Susanti Abdulkadir, Hidayat Ahmad, Tri Bella Angraini Suwandi

Abstract


Tuberculosis is a contagious infection caused by Mycobacterium tuberculosis. Tuberculosis can be cured if the patients receive maximum treatment, but most patients feel uncomfortable with the side effects of the antituberculosis drugs consumed so patients experience drop out during the treatment period. This research aims to evaluate the side effects of antituberculosis drugs and their management in patients with pulmonary TB at RSUD Dr. MM Dunda Limboto after receiving antituberculosis drugs category 1. This is observational descriptive research using the prospective method for 1 month with 45 patients as the sample. The finding shows that the most common side effects suffered by pulmonary TB patients after taking antituberculosis drugs category 1 are reddish urine by 31 patients (69%), malaise by 21 patients (47%), dizziness by 17 patients (38%), and nausea by 13 patients (29%). The side effect that occurs the least is an increase in the value of SGOT/SGPT by 2 patients (4%). The conclusion is that the most common side effects experienced are reddish urine, malaise, dizziness, and nausea. Handling of side effects of antituberculosis drugs is done by giving symptomatic drugs such as antiemetics, analgesics, antipyretics and vitamin B6 to patients who experience side effects.

Keywords


Side Effects; OAT; Tuberculosis

Full Text:

PDF

References


World Health Organization. (2020). Global tuberculosis report 2020. World Health Organization. https://apps.who.int/iris/handle/10665/336069

Pakaya, R., Olii, M. R., & Djafar, L. (2021). Distribusi Spasial Tuberkulosis Paru BTA Positif Berhubungan dengan Faktor Cuaca di Kota Gorontalo Tahun 2016-2018. 4, 12.

Kementrian Kesehatan, RI. (2018). Laporan-Riskesdas-2018-Nasional.pdf. Badan Penelitian dan Pengembangan KesehatanKementerian RI.

Kementrian Kesehatan, RI. (2020). Profil-Kesehatan-Indonesia-Tahun-2020.pdf.

Merzistya, A. N. A., & Rahayu, S. R. (2019). Kejadian Putus Berobat Penderita Tuberkulosis Paru. 13.

Abbas, A. (2017). Monitoring Of Side Effects Of Anti-Tuberculosis Drugs (ATD) On The Intensive Phase Treatment Of Pulmonary TB Patients In Makassar. Journal of Agromedicine and Medical Sciences, 3(1), 19. https://doi.org/10.19184/ams.v3i1.4093

Irmawartini, & Nurhaedah. (2017). Metodologi Penelitian. Kemenkes RI.

Johan, H., & Rita, S. (2018). Metode Penelitian Kesehatan.pdf. Gunadarma.

Musdalipah, M., Nurhikma, E., Karmilah, K., & Fakhrurazi, Muh. (2018). Efek Samping Obat Anti Tuberkulosis (Oat) Dan Penanganannya Pada Pasien Tuberkulosis (Tb) Di Puskesmas Perumnas Kota Kendari.Jurnal Ilmiah Manuntung, 4(1), 67. https://doi.org/10.51352/jim.v4i1.144

Pangaribuan, L., Kristina, Perwitasari, D., Tejayanti, T., & Bisara, D. (2020). Faktor-Faktor Yang Mempengaruhi Kejadian Tuberkulosis Pada Umur 15 Tahun Ke Atas Di Indonesia (Analisis Data Survei Prevalensi Tuberkulosis (Sptb) Di Indonesia 2013-2014). Puslitbang Upaya Kesehatan Masyarakat.

Nhamoyebonde, S., & Leslie, A. (2014). Biological Differences Between the Sexes and Susceptibility to Tuberculosis.Journal of Infectious Diseases, 209(suppl 3), S100–S106. https://doi.org/10.1093/infdis/jiu147

Carranza, C., Carreto-Binaghi, L. E., Guzmán-Beltrán, S., Muñoz-Torrico, M., Torres, M., González, Y., & Juárez, E. (2022). Sex-Dependent Differential Expression of Lipidic Mediators Associated with Inflammation Resolution in Patients with Pulmonary Tuberculosis. Biomolecules, 12(4), 490. https://doi.org/10.3390/biom12040490

Nurjana, M. A. (2015). Faktor Risiko Terjadinya Tuberculosis Paru Usia Produktif (15-49 Tahun) Di Indonesia.25(3), 8.

Oktavia, S., Mutahar, R., & Destriatania, S. (2016). Analysis Of Risk Factors For Pulmonary Tb Incidence In Work Area Health Kertapati Palembang.Jurnal Ilmu Kesehatan Masyarakat, 7(2), 124–138. https://doi.org/10.26553/jikm.2016.7.2.124-138

Suryo, Joko. (2010). Herbal : Penyembuh Gangguan Sistem Pernafasan. Yogyakarta. PT Bentang Pustaka

Fitria, E., Ramadhan, R., & Rosdiana, R. (2017). Karakteristik Penderita Tuberkulosis Paru di Puskesmas Rujukan Mikroskopis Kabupaten Aceh Besar. Sel Jurnal Penelitian Kesehatan, 4(1), 13–20. https://doi.org/10.22435/sel.v4i1.1441

Prihantana, A. S., & Wahyuningsih, S. S. (2016). Hubungan Pengetahuan Dengan Tingkat Kepatuhan Pengobatan Pada Pasien Tuberkulosis Di Rsud Dr. Soehadi Prijonegoro Sragen. 1, 8.

Permenkes, RI. (2016). Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis.

Untari, E. K., & Nansy, E. (2015). Kejadian Efek Samping Obat Anti Tuberkulosis (Oat) Kategori 1 Pada Pasien Tb Paru Di Unit Pengobatan Penyakit Paru-Paru (Up4) Provinsi Kalimantan Barat. 12.

Irianti, Kuswadi, Yasin, N., & Kusmaningtyas. (2016). Mengenal Anti- Tuberkulosis. Grafika Indah.

Kementerian Kesehatan Republik Indonesia. (2014). Pedoman Nasional Pengendalian Tuberkulosis. Kementerian Kesehatan Republik Indonesia. Jakarta

Pratiwi, N. K., Yowani, S., & Sajinadiyasa, K. (2016). Hubungan Lama Penggunaan Obat Anti-tuberkulosis dengan Efek Samping Pada Pasien TB MDR Rawat Jalan Di RSUP Sanglah Denpasar. Vol. 3 No. 2 : 39 . 48.

Fatmawati, U., & Kusmiati, T. (2019). Characteristics and the Side Effects of New MDR-TB Treatment in the Dr. Soetomo Hospital during 2016. Jurnal Respirasi, 3(3), 67. https://doi.org/10.20473/jr.v3-I.3.2017.67-73

Fraga, A., Oktavia, & Mulia. (2021). Evaluasi Penggunaan Obat Anti Tuberkulosis Pasien Baru Tuberkulosis Paru di Puskesmas Oebobo Kupang Tahun 2020. Vol. VIII No.1.




DOI: https://doi.org/10.37311/jsscr.v4i3.16657

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Journal Syifa Sciences and Clinical Research

EDITORIAL OFFICE OF JOURNAL SYIFA SCIENCES AND CLINICAL RESEARCH
  Department of Pharmacy, Gorontalo State University
Jl. Jenderal Sudirman No.6, Kota Gorontalo, Provinsi Gorontalo 96128, Indonesia
 Email: info.jsscr@ung.ac.id
Google Scholar : JOURNAL SYIFA SCIENCES AND CLINICAL RESEARCH

Creative Commons License

Journal Syifa Sciences and Clinical Research (JSSCR) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.